Strong Revenue Growth
Penumbra reported total revenue of $339.5 million for Q2 2025, representing a 13.4% year-over-year growth on a reported basis and 12.7% on a constant currency basis.
U.S. Thrombectomy Business Success
The U.S. thrombectomy business increased by 22.6% year-over-year to $188.5 million, with the U.S. VTE franchise growing by 42% year-over-year.
Gross Margin Improvement
The gross margin for Q2 2025 was 66%, up from 54.4% in Q2 2024, excluding a one-time inventory write-off.
Positive Clinical Trial Enrollment
Enrollment in the STORM-PE trial was completed ahead of schedule, with results expected to be presented at a major medical conference in the fall.
Increased Full-Year Revenue Guidance
Total revenue guidance for 2025 was increased to a range of $1.355 billion to $1.370 billion, representing 13% to 15% year-over-year growth.